Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "EPS"

550 News Found

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert
Healthcare | September 01, 2022

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved


Glenmark receives OAI from USFDA for Goa facility
News | August 28, 2022

Glenmark receives OAI from USFDA for Goa facility

Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.


Glenmark  receives OAI communication from US FDA
Drug Approval | August 24, 2022

Glenmark receives OAI communication from US FDA

The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest


Eugia Pharma receives USFDA pproval for Medroxyprogesterone Acetate injectable suspension
Drug Approval | August 24, 2022

Eugia Pharma receives USFDA pproval for Medroxyprogesterone Acetate injectable suspension

The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA


WuXi STA breaks ground for second manufacturing facility in US
News | August 19, 2022

WuXi STA breaks ground for second manufacturing facility in US

This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region


QPharma launches Ti OrderPoint 2
Digitisation | August 19, 2022

QPharma launches Ti OrderPoint 2

OrderPoint was designed as an advanced DTR solution from its first release in 2016.


Sun Pharma gets OAI from USFDA for Halol facility
Drug Approval | August 18, 2022

Sun Pharma gets OAI from USFDA for Halol facility

The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved


Eugia Pharma receives USFDA approval for Vasopressin Injection USP
Drug Approval | August 16, 2022

Eugia Pharma receives USFDA approval for Vasopressin Injection USP

The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.


Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery
Digitisation | August 04, 2022

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded


Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee
News | August 03, 2022

Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee

he US FDA has issued six observations pursuant to the completion of the audit.